Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ovarian Neoplasms 33Breast Neoplasms 26Triple Negative Breast Neoplasms 17Prostatic Neoplasms 16Fallopian Tube Neoplasms 11Neoplasms 9Fanconi Anemia, Complementation Group D1 7Endometrial Neoplasms 7Pancreatic Neoplasms 6Glioma 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Neoplasm Metastasis 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Osteosarcoma 3Lung Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinosarcoma 3Carcinoma, Renal Cell 3Wilms Tumor 2

Interventions

olaparib 2tetracarboxyphenylporphine 1testosterone enanthate 1testosterone 17 beta-cypionate 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Castration-Resistant Prostate Carcinoma × olaparib × Clear all
NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

University of Washington

Phase 2 Completed
36 enrolled 14 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

NCT04951492 2025-01-01

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

University of Washington

Phase 2 Terminated
2 enrolled 9 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡